Tafamidis meglumine - Pfizer

Drug Profile

Tafamidis meglumine - Pfizer

Alternative Names: Fx-1006A; FX1006A; PF-06291826; PF-6291826; Tafamidis; Vyndaqel

Latest Information Update: 16 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator FoldRx Pharmaceuticals
  • Developer Pfizer
  • Class Benzoxazoles; Carboxylic acids; Chlorobenzenes; Neuroprotectants; Small molecules
  • Mechanism of Action Amyloid inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyloid polyneuropathy; Cardiomyopathies
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Amyloid polyneuropathy
  • Phase III Cardiomyopathies

Most Recent Events

  • 29 Sep 2017 Pfizer initiates a phase-I trial in Healthy volunteers in USA (PO) (NCT03280173)
  • 14 Sep 2017 Pfizer plans a phase I trial in Healthy volunteers in Belgium (NCT03280173)
  • 31 Aug 2017 Pooled subgroup analysis of efficacy and adverse events data from three phase III trials in Amyloid polyneuropathy released by Pfizer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top